血脂管理与中国医保

汪朝晖; 廖玉华

doi:10.13201/j.issn.1001-1439.2023.09.002

血脂管理与中国医保

汪朝晖^1, ,,
廖玉华¹

- 华中科技大学同济医学院附属协和医院心内科(武汉，430022)

详细信息

通讯作者: 汪朝晖, E-mail: wuxiaohongtian@163.com

中图分类号: R54

收稿日期: 2023-08-29

刊出日期: 2023-09-13

Lipid management and Chinese medical insurance

WANG Zhaohui^1, ,,
LIAO Yuhua¹

- Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, china

More Information

Corresponding author: WANG Zhaohui, E-mail: wuxiaohongtian@163.com

Received Date: 29 August 2023

Publish Date: 13 September 2023

摘要

摘要: 近期，《中国血脂管理指南(2023)》公开发表，对动脉粥样硬化性心血管疾病(ASCVD)患者的血脂管理尤其是低密度脂蛋白胆固醇(LDL-C)水平提出了更严格的目标值和更精准的分层管理策略，多种降脂药物的联合治疗是分层管理血脂达标的有效措施。多年来降脂药物主要为原研进口，价格居高不下。近5年，国家医保局通过实施药品集中带量采购、医保国谈、国谈药“双通道”等措施，使降脂药物价格大幅下降，大大提高了ASCVD患者用药的可及性，为ASCVD患者的血脂分层管理提供了重要保障。
- 低密度脂蛋白胆固醇 /
- 血脂达标 /
- 分层管理 /
- 集中采购 /
- 国家谈判
Abstract: Recently, the Chinese Lipid Management Guideline(2023) was published, which proposed stricter target values and more accurate stratified management strategies for lipid management in atherosclerotic cardiovascular disease(ASCVD) patients, especially low-density lipoprotein cholesterol(LDL-C) levels. The combination treatment of multiple lipid-lowering drugs is an effective measure to reach the standard of stratified lipid management. For many years, lipid-lowering drugs are mainly imported from other countries, and their prices remain high. In the past five years, the National Medical Insurance Administration has implemented measures such as centralized drug procurement, national medical insurance negotiation, and "dual channel" of national drug negotiation, which has greatly reduced the price of lipid-lowering drugs, greatly improved the accessibility of drugs for patients with ASCVD, and provided an important guarantee for the stratified management of lipids in patients with ASCVD.
- low-density lipoprotein cholesterol /
- blood lipid targets /
- layer-management /
- centralized procurement /
- state bargaining

HTML全文

参考文献(17)

[1]	Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab andclinical outcomes in patients with cardiovascular disease[J]. N Engl J Med, 2017, 376(18): 1713-1722. doi: 10.1056/NEJMoa1615664
[2]	Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes[J]. N Engl J Med, 2015, 372(25): 2387-2397. doi: 10.1056/NEJMoa1410489
[3]	Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome[J]. N Engl J Med, 2018, 379(22): 2097-2107. doi: 10.1056/NEJMoa1801174
[4]	中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年)[J]. 中国循环杂志, 2023, 38(3): 237-271. doi: 10.3969/j.issn.1000-3614.2023.03.001
[5]	Cholesterol Treatment Trialists Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials[J]. Lancet, 2010, 376(9753): 1670-1681. doi: 10.1016/S0140-6736(10)61350-5
[6]	Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes[J]. N Engl J Med, 2015, 372(25): 2387-2397. doi: 10.1056/NEJMoa1410489
[7]	Scandinavian Simvastatin survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study(4S)[J]. Lancet, 1994, 344(8934): 1383-1389.
[8]	West of Scotland Coronary Prevention Group. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials[J]. Lancet, 1996, 348(9038): 1339-1342. doi: 10.1016/S0140-6736(96)04292-4
[9]	LaRosa JC, Grundy SM, Waters DD, et al. Treating to New Targets(TNT)Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease[J]. N Engl J Med, 2005, 352(14): 1425-1435. doi: 10.1056/NEJMoa050461
[10]	Wiviott SD, Cannon CP, Morrow DA, et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy[J]. J Am Coll Cardiol, 2005, 46(8): 1411-1416. doi: 10.1016/j.jacc.2005.04.064
[11]	Tang M, He J, Chen M, et al. "4+7" city drug volumebased purchasing and using pilot program in China and its impact[J]. Drug Discov Ther, 2019, 13(6): 365-369. doi: 10.5582/ddt.2019.01093
[12]	赵耀伟, 王成亮, 闫彬, 等. 以间断时间序列法分析带量采购政策对中标他汀类药物使用影响[J]. 医药导报, 2022, 41(8): 1234-1238.
[13]	彭倩雯, 徐斌, 张伟霞. 急性冠脉综合征患者原研与"带量采购"阿托伐他汀钙片疗效和安全性的回顾性比较[J]. 药物流行病学杂志, 2023, 32(4): 361-366. https://www.cnki.com.cn/Article/CJFDTOTAL-YWLX202304001.htm
[14]	Gitt AK, Lautsch D, Ferrieres J, et al. Low-density lipoprotein cholesterol in a global cohort of 57, 885 statin-treated patients[J]. Atherosclerosis, 2016, 255: 200-209. doi: 10.1016/j.atherosclerosis.2016.09.004
[15]	Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease[J]. N Engl J Med, 2017, 376(18): 1713-1722. doi: 10.1056/NEJMoa1615664
[16]	Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome[J]. N Engl J Med, 2018, 379(22): 2097-2107. doi: 10.1056/NEJMoa1801174
[17]	孙焕征, 曹人元, 任今今, 等. 医保国谈药"双通道"管理机制成效与展望[J]. 中国医疗保险[J]. 2023, (1): 12-15. https://www.cnki.com.cn/Article/CJFDTOTAL-YLBX202301002.htm